Passion for Innovation.
Compassion for Patients.™

Daiichi-Sankyo

Daiichi Sankyo Europe GmbH · 81366 Munich · Germany

Prof Dr Richard F. Schlenk
Head of NCT-Trial Center
National Center for Tumor Diseases
Im Neuenheimer Feld 130.3
69120 Heidelberg

Daiichi Sankyo Europe GmbH
Zielstattstrasse 48
81379 Munich · Germany
Phone +49 89 78080
Fax +49 89 7808267
service@daiichi-sankyo.eu
www.daiichi-sankyo.eu

Jan 19, 2018

Dear Professor Schlenk,

I am pleased to inform you that the Investigator-Initiated Study (IIS) Committee of Daiichi Sankyo Inc. (DSI) has approved supporting your study entitled **"Quizartinib and High-dose Ara-C plus Mitoxantrone in Relapsed/Refractory AML with FLT3-ITD".**

Please be aware that approval of your study proposals with funding in the total amount of approximately [redacted] is contingent upon review of the final protocols.

After the above is completed, approval will be pending our internal legal office review and preparation of a legal agreement.

The following information will be required by DSE before we can begin working on your legal agreement. Please submit the items indicated below at your earliest convenience.

- ☐ Name, phone, address, and fax number of a contract person in your institution's contract office
- ☐ Bank Account Details

A legal agreement has been drafted by Daiichi Sankyo Europe and will be forwarded to your legal department after the above mentioned information is available.

Please send all of the aforementioned documents via email to [redacted] at [redacted]@daiichi-sankyo.eu. You can reach [redacted] at +49 (0)89 [redacted].

If I can assist you in any way, please feel free to contact me.

Sincerely,

Heidi Anthoni, PhD
Daiichi Sankyo Europe
SM Medical Affairs Oncology & Biologics

cc: [redacted], PharmD, Global Medical Affairs Oncology
[redacted] PhD, Clinical Operations
[redacted], MAS, Global Medical Affairs Oncology, Clinical Operations